Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 112,611

Document Document Title
WO/2016/077437A1
The present invention is directed to methods of preconditioning neurons to reduce neuronal inflammation in a subject. Such methods include a step of administering apoaequorin to a subject, wherein the subject's neurons are preconditioned...  
WO/2016/073895A1
The invention provides substituted pyrazolo[l,5-a]pyrimidine and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gau...  
WO/2016/071211A1
The present invention provides a compound of formula (I), having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the pr...  
WO/2016/072599A1
The present invention relates to a pharmaceutical composition for treating autism spectrum disorders, containing clioquinol or a pharmaceutically acceptable salt thereof. In addition, the present invention relates to a food composition f...  
WO/2016/071283A1
Provided is a compound for use in medicine for inhibiting tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO), which compound comprises formula (I) wherein X1, X2, and X7, may be the same or different and each is in...  
WO/2016/072402A1
The present invention pertains to a compound having an exceptional effect for inhibiting retinoic-acid-receptor-related orphan receptors γt, or a pharmacologically acceptable salt thereof. A compound represented by general formula (I) (...  
WO/2016/073716A1
The present disclosure relates in general to methods for the treatment of neurodegenerative disease, such as Huntington's Disease, using compositions comprising cysteamine or cystamine or salts or derivatives thereof.  
WO/2016/072871A1
The invention relates to the Proline-Rich Polypeptide complex (PRP) derived from the mammalian colostrum for use in the treatment of the disorders and conditions related to the alterations of the Brain-Derived Neurotrophic Factor level a...  
WO/2016/073424A1
The invention provides a chemical entity of Formula (I): (I), wherein R1, R2, R3, and R4, have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range ...  
WO/2016/071767A1
The disclosure provides a dosage regimen using sustained-release buprenorphine formulations to produce therapeutic levels of buprenorphine in patients for the treatment of pain or opioid use disorders.  
WO/2016/073891A1
The invention provides substituted pyrrolo[l,2-a]pyrimi dines and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Ga...  
WO/2016/071121A1
The present invention pertains to novel analgesics useful for treating pain. BLT2 agonists were found to desensitize TRPV1 mediated signalling in sensory neurons. Thus the invention provides BLT2 agonists as novel pain therapeutics. Addi...  
WO/2016/071293A3
Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises formula (I) wherein X1, and X2 may be the same or different and each is independentl...  
WO/2016/070817A1
The present invention relates to the field of pharmaceutical engineering, and in particular relates to use of edaravone in preparing drugs for preventing and treating cerebral amyloid angiopathy (CAA). By administrating edaravone, the pr...  
WO/2016/072842A1
The invention pertains to the use of one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof in the manufacture of a product for treating, preventing or reducing the risk of occurrence of behavioral ...  
WO/2016/073693A3
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides encoding AADC for the treatment of Parkinson's Disease.  
WO/2016/072519A1
Provided is a cell population containing differentiated cells that can be obtained by inducing the differentiation of pluripotent stem cells, wherein the content ratio of undifferentiated pluripotent stem cells is 0.2% or less.  
WO/2016/071819A1
Embodiments of the invention relate to methods for treatment of age-related cognitive decline in a patient comprising administering to the patient a low dose of tetrahydrocannabinol (THC), preferably in an amount of 10-400 micrograms (µ...  
WO/2016/073828A1
Provided herein are methods for improving memory or cognitive function in a subject by administering a composition to the brain of the subject, where the composition comprises: i) a compound that increases expression of MALAT-1 long non-...  
WO/2016/073407A1
There are disclosed a series of quinuclidines having the Formula (I). which bind to the nicotinic α7 receptor and may be useful for the treatment of disorders of the central nervous system.  
WO/2016/073664A1
The disclosure is based on the discovery that aberrant immune responses are contributing to the pathogenicity of CCMs in patients, and that blocking those responses treats the CCM. Described herein is a method for treating CCMs in a pati...  
WO/2016/073889A1
The invention provides substituted imidazo[1,5-a]pyrimidines and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gau...  
WO/2016/072392A1
The purpose of the present invention is to provide an agent for promoting tau protein production containing a natural substance as the active ingredient, a therapeutic or prophylactic drug for disease caused by tau protein deficiency, an...  
WO/2016/073420A1
The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, R4, X, and Y have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range o...  
WO/2016/072522A1
The purpose of the present invention is to provide an agent for the prevention and/or treatment of Alzheimer's disease, the agent having a novel mechanism of action and reduced side effects. A polyphenol derivative having heightened lipo...  
WO/2016/073685A1
The present disclosure is directed to humanized anti-C1q antibodies and methods of using the same.  
WO/2016/067043A1
The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug d...  
WO/2016/066102A1
A use of maitake, maitake extract and/or maitake polysaccharide D component serving as an active ingredient in the preparation of an antidepressant drug; the drug is used to treat or prevent depressive disorder, and has a marked antidepr...  
WO/2016/067638A1
The present invention relates to novel compounds of a formula (I) or a pharmaceutically acceptable salt or solvate thereof, processes for their preparation, pharmaceutical compositions comprising them and their use in therapy, for exampl...  
WO/2016/066115A1
Provided is a compound as shown by formula I having an enzyme activity which can inhibit endocannabinoid hydrolases NAAA and/or FAAH, pharmaceutically acceptable salts, hydrates or solvates thereof, and a preparation method and a use of ...  
WO/2016/067143A1
The present invention relates to carboxamide derivatives. More particularly, it relates to N-(2-alkyleneimino-3-phenylpropyl)acetamide derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, RA, RB,...  
WO/2016/065585A1
The present invention is directed to piperidine isoxazole and isothiazole orexin compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treat...  
WO/2016/065419A1
Provided herein are methods and compositions for use in the treatment of depression, anxiety or a depressive or anxiety-related disorder. Embodiments describe the administration of orotic acid or a salt thereof, or the administration of ...  
WO/2016/067629A1
The present invention provides a technique for treating retinal epithelium and/or nerves. More specifically, the present invention is an agent for the treatment or prevention of retinal disease or the like and/or a disease, disorder, or ...  
WO/2016/068186A1
[Problem] To provide a new intestinal muscle layer thinning preventing/treating composition, diarrhea preventing/treating composition, and weaning stress alleviating composition. [Solution] The present invention was achieved after confir...  
WO/2016/069760A1
Treatment of dementia (e.g. Alzheimers disease) using a polynucleotide agent (e.g. DNA or RNA) that contains a nucleotide sequence that encodes a vascular endothelial growth factor (VEGF) polypeptide. The polynucleotide agent is administ...  
WO/2016/068267A1
Provided is an agent for improving sickness behavior symptoms. The agent for improving sickness behavior symptoms comprises a liver hydrolysate as an active ingredient.  
WO/2016/067265A1
The invention relates to the use of a reverse-transcriptase inhibitor in the prevention or treatment of a degenerative disease.  
WO/2016/069875A1
Provided are compositions comprising (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate, or hydrate thereof, optionally in combination with a supplemental agent, and methods for reduc...  
WO/2016/065587A1
The present invention is directed to pyrazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the pyrazole compounds described herein in the potential treatment or prevention of neur...  
WO/2016/068616A1
The present invention relates to placenta-derived cells excreting C3 or C1R complement proteins, a pharmaceutical composition containing same, and a method for treating diseases using the placenta-derived cells. The placenta-derived cell...  
WO/2016/066755A2
The present invention refers to 4-amino-substituted pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine derivatives of formula I and IV able to target the Src family kinases (SFKs) such as Src, Fyn and Hck tyrosine kinases as well as ...  
WO/2016/066582A1
The present invention relates to method of inhibiting protein kinase activity which comprises contacting a protein kinase with a compound of formula (I), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solva...  
WO/2016/069801A1
Some embodiments include bacterial species for use in treatment of one or more autism spectrum disorder (ASD), and/or schizophrenia symptoms in a subject in need thereof. The bacterial species can include Bacteroides (e.g., B. fragilis, ...  
WO/2016/069510A1
The present invention is directed to piperidine oxadiazole and thiadiazole orexin compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential trea...  
WO/2016/067297A1
The compositions and compounds of formula I, formula II, formula III and formula IV which includes a salt of valproic acid or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as ph...  
WO/2016/065481A1
There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stim...  
WO/2016/066700A1
The present invention is directed to alpha-MSH analogues for treatment of neurodegenerative disorders.  
WO/2016/070181A1
Cotinine, a natural product present in tobacco leaves that has antidepressant effects on locomotor activity and sensorimotor abilities, was tested on depressive-like behavior, neuroinflammation and neurogenesis. When administered to mice...  
WO/2016/069854A1
Provided herein are compositions containing the drug OSU-03012 (AR-12) in combination with one or more drugs selected from multi-kinase inhibitors, HDAC inhibitors, folate antimetabolites, DNA alkylating agents, and sphingosine- 1 -phosp...  

Matches 401 - 450 out of 112,611